Published in Clin Chem on April 01, 1982
American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001--testing for early lung cancer detection. CA Cancer J Clin (2001) 4.41
Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res (1994) 4.32
Diagnostic criteria for schwannomatosis. Neurology (2005) 3.41
In vivo magnetic resonance imaging of transgene expression. Nat Med (2000) 3.35
Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med (1999) 2.42
Fibroblast-mediated acceleration of human epithelial tumor growth in vivo. Proc Natl Acad Sci U S A (1990) 2.34
Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Cancer Res (1986) 2.30
Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors. Hum Gene Ther (1998) 2.13
Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res (1997) 2.02
Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. J Clin Oncol (1983) 2.01
The prognostic importance of Gleason grade in prostatic adenocarcinoma: a long-term follow-up study of 648 patients treated with radiation therapy. Int J Radiat Oncol Biol Phys (1995) 2.00
Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer. J Natl Cancer Inst (1996) 1.99
Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nat Cell Biol (2011) 1.98
Simulated brain tumor growth dynamics using a three-dimensional cellular automaton. J Theor Biol (2000) 1.94
Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol (2000) 1.93
Spermatic cord sarcoma: outcome, patterns of failure and management. J Urol (2001) 1.88
Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res (1991) 1.87
Pattern of self-organization in tumour systems: complex growth dynamics in a novel brain tumour spheroid model. Cell Prolif (2001) 1.86
c-met proto-oncogene expression in benign and malignant human prostate tissues. J Urol (1995) 1.83
Isolation and characterization of cDNA clones to mouse macrophage and human endothelial cell tissue transglutaminases. J Biol Chem (1991) 1.60
Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. J Natl Cancer Inst (1998) 1.60
p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst (1993) 1.54
Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J Virol (2000) 1.54
Serum testosterone--a significant determinant of metastatic relapse for irradiated localized prostate cancer. Urology (1997) 1.52
Quality of life after salvage cryotherapy: the impact of treatment parameters. J Urol (1999) 1.51
An infectious transfer and expression system for genomic DNA loci in human and mouse cells. Nat Biotechnol (2001) 1.46
p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. J Urol (1999) 1.46
Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Mol Ther (2001) 1.45
Single-step conversion of cells to retrovirus vector producers with herpes simplex virus-Epstein-Barr virus hybrid amplicons. J Virol (1999) 1.43
Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res (1992) 1.43
[Spinal arachnoiditis as a complication of peridural anesthesia]. Medicina (B Aires) (1993) 1.40
Polymorphic forms of human apolipoprotein[a]: inheritance and relationship of their molecular weights to plasma levels of lipoprotein[a]. J Lipid Res (1990) 1.33
Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene Ther (2003) 1.31
Measuring transferrin receptor gene expression by NMR imaging. Biochim Biophys Acta (1998) 1.31
Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models. Gene Ther (2006) 1.29
Therapy and prognosis for male anterior urethral carcinoma: an update. Urology (1994) 1.28
MicroRNAs and glioblastoma; the stem cell connection. Cell Death Differ (2009) 1.27
Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum Gene Ther (1997) 1.26
Indications, complications and results with silicone stents. Ophthalmology (1979) 1.25
Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique. Am J Pathol (1997) 1.23
Different growth pattern and biologic behavior of human renal cell carcinoma implanted into different organs of nude mice. J Natl Cancer Inst (1987) 1.21
B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells. J Virol (1999) 1.18
O-Glycosylation in sprouting neurons in Alzheimer disease, indicating reactive plasticity. J Neuropathol Exp Neurol (2001) 1.16
Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res (1994) 1.15
Lack of prostate cancer radiosensitization by androgen deprivation. Int J Radiat Oncol Biol Phys (2001) 1.14
Relationship of Ki-67 labeling index to DNA-ploidy, S-phase fraction, and outcome in prostate cancer treated with radiotherapy. Prostate (1999) 1.14
An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat Biotechnol (1998) 1.14
Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J Urol (1997) 1.13
Stage C adenocarcinoma of the prostate. An analysis of 551 patients treated with external beam radiation. Cancer (1987) 1.13
Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. Cancer Res (2001) 1.12
Isolation, purification, and partial characterization of type V-A hemagglutinin from Escherichia coli GV-12, O1:H-. J Bacteriol (1982) 1.11
Apoptosis suppression by bcl-2 is correlated with the regulation of nuclear and cytosolic Ca2+. Oncogene (1996) 1.11
Cellular automaton of idealized brain tumor growth dynamics. Biosystems (2000) 1.10
Early androgen ablation for stage D1 (N1 to N3, M0) prostate cancer: prognostic variables and outcome. J Urol (1994) 1.09
External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. Int J Radiat Oncol Biol Phys (2000) 1.08
Homozygous deletions at 8p22 and 8p21 in prostate cancer implicate these regions as the sites for candidate tumor suppressor genes. Oncogene (1995) 1.07
Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16. Oncogene (2008) 1.06
Stereotactic radiofrequency thermal cingulotomy for obsessive compulsive disorder. J Neuropsychiatry Clin Neurosci (1990) 1.06
Emergence of a subpopulation in a computational model of tumor growth. J Theor Biol (2000) 1.06
Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: a gene-marking and neuropathological study. J Neurosurg (2000) 1.06
Directing systemic oncolytic viral delivery to tumors via carrier cells. Cytokine Growth Factor Rev (2010) 1.06
Can cancer cells transform normal host cells into malignant cells? Br J Cancer (1997) 1.06
An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. FASEB J (2000) 1.06
Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline. Cancer Res (1993) 1.05
Model systems of prostate cancer: uses and limitations. Cancer Metastasis Rev (1999) 1.05
Consistent expression of an epithelial cell adhesion molecule (C-CAM) during human prostate development and loss of expression in prostate cancer: implication as a tumor suppressor. Cancer Res (1995) 1.04
Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector. Gene Ther (1998) 1.04
Sentinel lymph node dissection for penile carcinoma: the M. D. Anderson Cancer Center experience. J Urol (1995) 1.04
Co-inoculation of tumorigenic rat prostate mesenchymal cells with non-tumorigenic epithelial cells results in the development of carcinosarcoma in syngeneic and athymic animals. Int J Cancer (1989) 1.03
Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors. Hum Gene Ther (1994) 1.03
Comparison of intracerebral inoculation and osmotic blood-brain barrier disruption for delivery of adenovirus, herpesvirus, and iron oxide particles to normal rat brain. Am J Pathol (1995) 1.03
Experimental catecholamine-induced myocardial necrosis. I. Morphology, quantification and regional distribution of acute contraction band lesions. J Mol Cell Cardiol (1985) 1.02
The efficacy and complications of salvage cryotherapy of the prostate. J Urol (1997) 1.02
Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. Ann Surg (1996) 1.02
Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. Gene Ther (1994) 1.02
Long-term followup of incontinence and obstruction after salvage cryosurgical ablation of the prostate: results in 143 patients. J Urol (1997) 1.02
Herpes vector-mediated delivery of marker genes to disseminated central nervous system tumors. Hum Gene Ther (1996) 1.02
Superimposed histologic and genetic mapping of chromosome 17 alterations in human urinary bladder neoplasia. Oncogene (1997) 1.01
Transgene inheritance and retroviral infection contribute to the efficiency of gene expression in solid tumors inoculated with retroviral vector producer cells. Gene Ther (1995) 1.01
Small cell carcinoma of prostate associated with myasthenic (Eaton-Lambert) syndrome. Urology (1989) 1.01
Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys (1995) 1.01
Primary lymphoma of peripheral nerve: report of four cases. Am J Surg Pathol (2000) 1.00
Progress and prospects: gene therapy clinical trials (part 2). Gene Ther (2007) 1.00
Gene therapy for brain tumors. Brain Pathol (1995) 1.00
Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res (1999) 1.00
Chemotherapy of extragonadal germ cell tumors. J Clin Oncol (1985) 0.99
31P Nuclear magnetic resonance measurement of cardiac pH in perfused guinea-pig hearts. J Mol Cell Cardiol (1979) 0.99
Inhibition of NF2-negative and NF2-positive primary human meningioma cell proliferation by overexpression of merlin due to vector-mediated gene transfer. J Neurosurg (1999) 0.99
Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum Gene Ther (1994) 0.98
New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol. Hum Gene Ther (1998) 0.97
Prostatic intraepithelial neoplasia and invasive prostatic adenocarcinoma in cystoprostatectomy specimens. Urology (1989) 0.97
Trisomy 7: a potential cytogenetic marker of human prostate cancer progression. Genes Chromosomes Cancer (1994) 0.96
Comparative analyses of transgene delivery and expression in tumors inoculated with a replication-conditional or -defective viral vector. Cancer Res (2001) 0.95
A feasibility study of cryotherapy followed by radical prostatectomy for locally advanced prostate cancer. J Urol (1999) 0.95
Infectious delivery of the 132 kb CDKN2A/CDKN2B genomic DNA region results in correctly spliced gene expression and growth suppression in glioma cells. Gene Ther (2004) 0.95
Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector. Ann Surg (1998) 0.95
Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era. Cancer (1997) 0.95
Analytical techniques for cell fractions. XXVII. Use of heart proteins as reference standards in two-dimensional electrophoresis. Anal Biochem (1980) 0.94
The subtemporal-transpetrous approach for excision of petroclival tumors. Am J Otol (1996) 0.94